CTRI/2023/10/058595尚未招募4 期
A Prospective open label study to evaluate the safety, efficacy and tolerability of mirabegron with solifenacin combination compared to their monotherapies in overactive bladder patients. - NI
Dr Muhammed Munavvir0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •OAB symptoms since 3 weeks
- •1 week drug free period for OAB treatment (mirabegron remains 5-6 days to be completely eliminated from the body [18])
- •Newly diagnosed OAB patient
- •Patients of both gender
排除标准
- •Known case of Pregnant and lactating women
- •Neurogenic bladder
- •Patient with significant stress/ urge
- •UTI, prostatis, interstitial cystitis, bladder stone, malignant pelvic disease
- •Urinary retention
- •End Stage Renal Disease
- •Diabetic nephropathy
- •Uncontrolled Hypertension[14] (Systolic pressure =180mmHg and diastolic pressure =110mmHg)
研究者
相似试验
招募中
3 期
Clinical trial on over weight subjectsCTRI/2022/08/044574Kerala Ayurveda Limited
尚未招募
3 期
Clinical trial on Sleep problemsCTRI/2023/10/059312Kerala Ayurveda Limited
进行中（未招募）
不适用
A clinical trial to test the safety of Cell Bandage, a product made from the patient's own bone marrow stem cells, in the treatment of meniscus (cartilage) tears in the kneeEUCTR2010-024162-22-GBAzellon Ltd10
进行中（未招募）
1 期
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and CirrhosisHepatitis C InfectionMedDRA version: 17.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-001496-31-ATAbbVie Deutschland GmbH & Co. KG160
进行中（未招募）
1 期
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Coadministered with Ribavirin in Adults with Genotype 4 Chronic Hepatitis C Virus Infection and CirrhosisEUCTR2014-001496-31-ESAbbVie Deutschland GmbH & Co. KG160